ClinicalTrials.gg
TerminatedNCT05126433JAZZ EMERGE201Updated Feb 28, 2025Results posted

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

A Phase 2 interventional study of Lurbinectedin in Advanced Solid Tumor, Metastatic Solid Tumor and Urothelial Cancer, sponsored by Jazz Pharmaceuticals. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Termination of this study was a business decision made during portfolio review.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
873rd of 1,863
47 · median 43
Started
2022
with 105 others
Phase 2
566 of 2,054
60 open now
Registered
1,620th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 873rd largest by enrollment of the 1,863 interventional ones that give a count, is one of 106 that started in 2022, is one of 566 in phase 2, and was the 1,620th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.

Read the detailed description

This phase 2, multicenter, open-label study is designed to assess the safety and efficacy of lurbinectedin monotherapy in 3 cohorts of participants with high-unmet medical need: advanced (metastatic and/or unresectable) urothelial cancer (UC), poorly differentiated neuroendocrine carcinomas (PD-NEC), and a homologous recombination deficient-positive malignancies agnostic cohort.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Urothelial Cancer
  • Poorly Differentiated Neuroendocrine Carcinomas
  • Homologous Recombination Deficient-Positive Malignancies Agnostic

Browse trials for

Keywords

  • Lurbinectedin
  • Monotherapy
  • Urothelial cancer
  • Poorly differentiated neuroendocrine carcinomas
  • Homologous recombination deficient-positive malignancies agnostic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. ≥ 18 years of age
  3. (ECOG) performance status of 0 or 1
  4. Adequate organ and bone marrow function
  5. Has per (RECIST) v1.1.
  6. Have advanced (/unresectable) cancers in one of the following:

    1. or cytologically confirmed urothelial cancer
    2. Histologically or cytologically confirmed poorly differentiated neuroendocrine carcinoma
    3. Histologically or cytologically confirmed homologous recombination deficient-positive agnostic, which may include endometrial, biliary tract, urothelial, breast (TNBC or HR+- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation
  7. Adequate precautions

Exclusion criteria

Exclusion Criteria:

  1. Known symptomatic central nervous system (CNS) requiring
  2. History of prior within 2 years of enrollment
  3. cardiovascular disease
  4. Active infection requiring systemic therapy
  5. Significant non-neoplastic liver disease
  6. Prior treatment with trabectedin or lurbinectedin
  7. Treatment with an agent within 4 weeks of enrollment
  8. Received with 4 weeks of first dose
  9. Prior allogeneic bone marrow or solid organ transplant
  10. Positive virus (HBV) or virus (HCV) infection at screening
  11. Positive (HIV) infection at screening
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Urothelial Cancer Cohort

    Participants with advanced (metastatic and/or unresectable) urothelial carcinoma who have progressed on platinum-containing regimen (prior therapies may include but are not limited to immune checkpoint inhibitor, enformumab vendotin, or sacituzumab govitecan) will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.

    Drug: Lurbinectedin

  • Experimental
    Poorly Differentiated Neuroendocrine Carcinomas Cohort

    Participants with advanced (metastatic and/or unresectable) poorly differentiated neuroendocrine carcinomas who received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.

    Drug: Lurbinectedin

  • Experimental
    Homologous Recombination Deficient-Positive Malignancies Agnostic Cohort

    Participants with advanced (metastatic and/or unresectable) endometrial, biliary tract, urothelial, breast (TNBC or HR+HER2- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation and received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.

    Drug: Lurbinectedin

Interventions

  • Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)

06

What researchers measure

Primary outcomes

  1. Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

    The ORR is defined as the proportion of participants whose best overall response (BOR) is investigator-assessed confirmed complete response (CR) or partial response (PR) using the RECIST v1.1 criteria. BOR is defined as the best response recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1, or the date of subsequent anticancer therapy, death due to any cause, loss to follow-up, or study discontinuation, whichever occurs first.

    Time frame: Baseline to disease progression or death, up to 36 weeks.

Secondary outcomes

  1. Investigator-Assessed Progression Free Survival (PFS) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

    PFS is defined as the time from the first dosing date to the date of first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Baseline to disease progression or death, up to 36 weeks

  2. Investigator-Assessed Time-To-Response (TTR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

    TTR is defined as the time from the first dosing date to the date of the first confirmed response (complete response \[CR\] or partial response \[PR\]), as assessed by the investigators.

    Time frame: Baseline to disease progression or death, up to 36 weeks

  3. Investigator-Assessed Duration of Response (DOR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

    DOR is defined as the time from the first confirmed response (complete response \[CR\] or partial response \[PR\]) to the date of the first documented tumor progression as determined using RECIST v1.1 criteria or death due to any cause, whichever occurs first

    Time frame: Baseline to disease progression or death, up to 36 weeks

  4. Investigator-assessed Disease Control Rate (DCR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

    DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed complete response (CR), or partial response (PR), or stable disease (SD) using the RECIST v1.1 criteria.

    Time frame: Baseline to disease progression or death, up to 36 weeks.

  5. Overall Survival (OS) in Participants Treated With Lurbinectedin

    OS is defined as the time from the first dosing date to the date of death from any cause. A participant who has not died will be censored at the last known alive date

    Time frame: Baseline and every 3 months, up to 16 months

07

Results

Posted Feb 28, 2025

Participant flow

A total of 47 participants who met all eligibility criteria were enrolled and received treatment were included

Participant flow — Overall Study
MilestoneUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
Started151220
Completed000
Not completed151220
Withdrew: Withdrawal by subject304
Withdrew: Death935
Withdrew: Study terminated by sponsor012
Withdrew: Progressive disease143
Withdrew: Sponsor decision- no further os follow up required246

Outcome measures

PrimaryInvestigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

The ORR is defined as the proportion of participants whose best overall response (BOR) is investigator-assessed confirmed complete response (CR) or partial response (PR) using the RECIST v1.1 criteria. BOR is defined as the best response recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1, or the date of subsequent anticancer therapy, death due to any cause, loss to follow-up, or study discontinuation, whichever occurs first.

Time frame:
Baseline to disease progression or death, up to 36 weeks.
Reported as:
Count of participants · Participants
Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
ParticipantsUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1021
SecondaryInvestigator-Assessed Progression Free Survival (PFS) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

PFS is defined as the time from the first dosing date to the date of first documented disease progression or death due to any cause, whichever occurs first.

Time frame:
Baseline to disease progression or death, up to 36 weeks
Reported as:
Median · months
Investigator-Assessed Progression Free Survival (PFS) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
monthsUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
Investigator-Assessed Progression Free Survival (PFS) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.11.46 (0.89 to 3.32)2.07 (1.18 to 2.89)1.38 (1.35 to 2.79)
SecondaryInvestigator-Assessed Time-To-Response (TTR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

TTR is defined as the time from the first dosing date to the date of the first confirmed response (complete response \[CR\] or partial response \[PR\]), as assessed by the investigators.

Time frame:
Baseline to disease progression or death, up to 36 weeks
Reported as:
Median · months
Investigator-Assessed Time-To-Response (TTR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
monthsUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
Investigator-Assessed Time-To-Response (TTR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1—2.76 (2.7 to 2.8)1.31
SecondaryInvestigator-Assessed Duration of Response (DOR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

DOR is defined as the time from the first confirmed response (complete response \[CR\] or partial response \[PR\]) to the date of the first documented tumor progression as determined using RECIST v1.1 criteria or death due to any cause, whichever occurs first

Time frame:
Baseline to disease progression or death, up to 36 weeks
Reported as:
Median · months
Investigator-Assessed Duration of Response (DOR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
monthsUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
Investigator-Assessed Duration of Response (DOR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1—5.67 (2.8 to 8.6)2.79
SecondaryInvestigator-assessed Disease Control Rate (DCR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed complete response (CR), or partial response (PR), or stable disease (SD) using the RECIST v1.1 criteria.

Time frame:
Baseline to disease progression or death, up to 36 weeks.
Reported as:
Count of participants · Participants
Investigator-assessed Disease Control Rate (DCR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
ParticipantsUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
Investigator-assessed Disease Control Rate (DCR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1457
SecondaryOverall Survival (OS) in Participants Treated With Lurbinectedin

OS is defined as the time from the first dosing date to the date of death from any cause. A participant who has not died will be censored at the last known alive date

Time frame:
Baseline and every 3 months, up to 16 months
Reported as:
Median · months
Overall Survival (OS) in Participants Treated With Lurbinectedin
monthsUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
Overall Survival (OS) in Participants Treated With Lurbinectedin4.99 (0.92 to 14.52)NA (2.66 to NA)NA (2.89 to NA)

Adverse events

Collected over Adverse events were collected from the start of dosing of study drug up until 30 days after last study dose, up to approximately 10 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Urothelial Cancer (UC) Cohort9/15 (60%)9/15 (60%)15/15 (100%)
Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort3/12 (25%)3/12 (25%)12/12 (100%)
Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort5/20 (25%)8/20 (40%)19/20 (95%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
FatigueGeneral disorders0/150/122/20
Neutrophil count decreasedInvestigations1/150/122/20
Acute kidney injuryRenal and urinary disorders0/150/122/20
Cardiac ArrestCardiac disorders0/151/120/20
Mouth haemorrhageGastrointestinal disorders0/151/120/20
PneumoniaInfections and infestations0/151/120/20
Cerebrovascular accidentNervous system disorders0/151/120/20
NauseaGastrointestinal disorders1/150/120/20
VomitingGastrointestinal disorders1/150/120/20
Chest painGeneral disorders1/150/120/20
Most frequent other events
Showing 10 of 85
Most frequent other events
EventUrothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort
AnaemiaBlood and lymphatic system disorders9/152/122/20
ConstipationGastrointestinal disorders2/156/124/20
NauseaGastrointestinal disorders4/156/129/20
FatigueGeneral disorders6/156/128/20
Platelet count decreasedInvestigations7/151/126/20
Neutrophil count decreasedInvestigations6/151/123/20
VomitingGastrointestinal disorders4/152/127/20
DiarrhoeaGastrointestinal disorders2/154/123/20
Alanine aminotransferase increasedInvestigations3/154/125/20
Blood alkaline phosphatase increasedInvestigations5/154/122/20

Baseline characteristics

The baseline demographic characteristics were assessed in the Safety Analysis Set.

Age, Categorical
Age, Categorical(Participants)Urothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) CohortTotal
<=18 years0000
Between 18 and 65 years751123
>=65 years87924
Sex: Female, Male
Sex: Female, Male(Participants)Urothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) CohortTotal
Female151218
Male147829
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Urothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) CohortTotal
Hispanic or Latino0213
Not Hispanic or Latino1591842
Unknown or Not Reported0112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Urothelial Cancer (UC) CohortPoorly Differentiated Neuroendocrine Carcinomas (PD-NEC) CohortHomologous Recombination Deficient-Positive Malignancies Agnostic (HRD) CohortTotal
American Indian or Alaska Native0000
Asian1102
Native Hawaiian or Other Pacific Islander0000
Black or African American1214
White1181736
More than one race1001
Unknown or Not Reported1124
08

Study locations

17 sites
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Eastern Connecticut Hematology and Oncology
    Norwich, Connecticut 06360, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Sarah Cannon, Florida Cancer Specialist
    Saint Petersburg, Florida 33705, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Pikeville Medical Center
    Pikeville, Kentucky 41501, United States
  • Dana Farber
    Boston, Massachusetts 02215, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68124, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28203, United States
  • Sarah Cannon, Zangmeister Cancer Center
    Columbus, Ohio 43219, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Hillman Cancer Center Investigational Drug Service
    Pittsburgh, Pennsylvania 15232, United States
  • Bon Secours Hematology and Oncology
    Greenville, South Carolina 29607, United States
  • Sarah Cannon, Tennesse Oncology
    Nashville, Tennessee 37203, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Data sharing details ↗ · www.jazzpharma.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Dec 2023, 21 months.

Results were first posted in Feb 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Nov 19, 2021
StartActual
Mar 3, 2022
Primary completionActual
Dec 20, 2023
CompletionActual
Dec 20, 2023
Results first posted
Feb 28, 2025
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05126433
Collaborators
Jazz Pharmaceuticals Ireland Limited
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Mar 3, 2022
Primary completion
Dec 20, 2023
Completion
Dec 20, 2023
Results posted
Feb 28, 2025
Last update
Feb 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion